Publications & Presentations

Journal Publications

FNAIT Program

An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study. Journal of Thrombosis and Haemostasis. Geisen C., Kjaer M., Fleck E., Skogen B., Armstrong R., Behrens F., Bhagwagar Z., Braeuninger S., Mortberg A., Juel Olsen K., Martin Gasto´ n Schäfer, S., Walter C., Seifried E., Wikman A., Kjeldsen-Kragh J., Koehm, M., 2023;21(4):838–849. https://doi.org/10.1016/j.jtha.2022.11.041
Prophylactic Administration of HPA-1a–Specific Antibodies Prevents Fetal/Neonatal Alloimmune Thrombocytopenia in Mice. Blood. Zhi H., Sheridan D., Newman D.K., Newman P.J., 2022;140(20):2146–2153. doi: 10.1182/blood.2022015666.
Protecting the Fetus from FNAIT. Blood. Semple J.W., Kapur R., 2022;140(20):2097–2099. doi: 10.1182/blood.2022017937.

Scientific Presentations

FNAIT Program

Academy of Managed Care Pharmacy (AMCP) Annual Meeting, April 2024
Fetal and Neonatal Alloimmune Thrombocytopenia: A Systematic Literature Review and Meta-analysis of Adverse Pregnancy-Related Outcomes to Support the Development of a Novel Prophylactic Therapeutic
Andrea V Margulis, Nuria Riera-Guardia, Brian Calingaert, Mark P Fletcher, Kiran C Patki, Elena Rivero-Ferrer, Ethan Weiner, Róisín Armstrong, RTI Health Solutions, Barcelona, Spain; RTI Health Solutions, Research Triangle Park, NC, United States; Rallybio, New Haven, CT, United States
65th American Society of Hematology (ASH) Annual Meeting, December 2023
Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): An International, Prospective, Natural History Study
31st Congress of the International Society of Thrombosis and Haemostasis (ISTH), June 2023
Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
XXIX Congress of the International Society on Thrombosis and Haemostasis (ISTH), July 2021
Rapid and Complete Clearance of HPA-1a Mismatched Platelets in a Human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a Hyperimmune Plasma Derived Polyclonal Anti-HPA-1a Antibody
Geisen C., Fleck E., Schäfer S.M.G., Walter C., Braeuninger S., Olsen K., Bhagwagar Z., Mortberg A., Wikman A., Kjaer M., Kjeldsen-Kragh J., Behrens F., Seifried E., Köhm M.; Res Pract Thromb Haemost. 2021;5 (Suppl 2).

Complement Dysregulation Program

29th International Complement Workshop (ICW), September 2023

Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody® molecule linked to an Albumod® albumin binding domain